• Home

  • HEALTH CARE

  • HEALTHY LIFESTYLE

  • HYGIENE

  • COSMETICS

  • FOR HIM

  • PREGNANCY AND MOTHERHOOD

  • CHILD

    2. HEALTH CARE
    3. Eglonyl 50mg 30 capsules — Made in France — Free Delivery

    Eglonyl 50mg 30 capsules — Made in France — Free Delivery


    Brand: VEVICU
    Product Code: Eglonyl 50mg
    Availability: In Stock
    $27.99
    Add to Cart

    Pharmacological properties

    A neuroleptic agent. Sulpiride is a selective dopamine d2/d3 receptor antagonist. in patients with psychosis with negative symptoms, sulpiride is effective at a dose of 150-600 mg / day; at this dose, sulpiride has practically no effect on positive symptoms. at a dose of 0.6-1.6 g / day improves the condition of patients with acute or chronic psychosis with positive symptoms. only very high doses of sulpiride have a sedative effect.
    After i / m administration at a dose of 100 mg, the maximum concentration of the preparation in blood plasma (about 2.2 mg / l) is reached after 30 minutes. When administered orally, sulpiride is absorbed in the digestive tract within 4.5 hours, the maximum concentration of the preparation in the blood plasma ranges from 0.5-1.8 mg / l after taking a dose of 200 mg. Bioavailability of oral forms - 25-35% with wide individual fluctuations; The concentration of sulpiride in plasma is proportional to the dose. Sulpiride is rapidly distributed in body tissues, mainly in the kidneys and liver; a small amount penetrates the BBB. Less than 40% of the preparation binds to plasma proteins; the distribution ratio of erythrocytes and blood plasma is 1. The amount of the preparation that penetrates into breast milk is 1/1000 of the daily dose. Sulpiride is poorly metabolized in the body. The half-life is 7 hours; the volume of distribution in the equilibrium state is 0.94 l / kg (0.6–1.5 l / kg) of body weight. The total clearance is 126 ml / min. Sulpiride is excreted mainly by the kidneys by glomerular filtration.

    Indications

    Acute and chronic psychosis; neurotic, psychofunctional and psychoaffective disorders associated with somatic diseases.

    Application

    Initial treatment is carried out in / m administration of the preparation, after which they switch to oral administration. with neurotic, psychofunctional and psychoaffective disorders associated with somatic conditions:
    Adults - 100-200 mg / day.
    Children over 6 years of age: 5 mg/kg of body weight per day (if necessary, this dose may be increased to 10 mg/kg).
    In acute and chronic psychosis, the dose is set in accordance with the predominant symptoms: negative - 200-600 mg / day, positive - 800-1600 mg / day.

    Contraindications

    It is not recommended to prescribe eglonil for diagnosed or suspected pheochromocytoma, since during treatment with antidopamine preparations, including some benzamides, cases of severe hypertension have been described in individuals with pheochromocytoma, as well as in prolactin-dependent tumors (for example, pituitary prolactinoma and breast cancer).

    Side effects

    Sedation, drowsiness, early dyskinesia (spasmodic torticollis, oculogeric crises, trismus, decreasing with the appointment of anticholinergic antiparkinsonian preparations), extrapyramidal symptoms, the severity of which is partially reduced with the appointment of anticholinergic antiparkinsonian preparations, tardive dyskinesia that develops with prolonged use of antipsychotics (anticholinergic antiparkinsonian preparations are ineffective and may worsen the patient's condition), postural hypotension, impotence, frigidity, amenorrhea, galactorrhea, gynecomastia, hyperprolactinemia, weight gain.

    special instructions

    With the development of hyperthermia, sulpiride should be canceled. hyperthermia may be a manifestation of neuroleptic malignant syndrome (pallor, hyperthermia and autonomic dysfunction). this precaution is especially important when using the preparation in high doses.
    Care should be taken when treating elderly patients who are more susceptible to the action of the preparation
    Since sulpiride is excreted by the kidneys, in patients with severe renal insufficiency, the preparation should be used at reduced doses and an intermittent treatment regimen should be used.
    Patients with epilepsy require more careful monitoring (clinical and, if necessary, EEG), since sulpiride lowers the seizure threshold.
    In patients with Parkinson's disease, sulpiride is prescribed with caution according to strict indications.
    In patients with aggressive behavior or agitation with impulsivity, sulpiride should be administered together with sedatives.
    In children whose mothers took sulpiride at a low dose (approximately 200 mg / day) during pregnancy, no increase in the incidence of birth defects was observed. There is no experience of using the preparation in higher doses. There is also no data on the potential effect of neuroleptics taken during pregnancy on fetal brain development. It seems reasonable, if possible, to reduce the dose and reduce the duration of treatment with the preparation during pregnancy. In newborns whose mothers underwent long-term treatment with high doses of antipsychotics, several cases of extrapyramidal syndrome have been described. It is recommended to monitor the neurological status of children born to mothers who received the preparation for some time after birth.
    Since sulpiride passes into breast milk, breast-feeding should be discontinued during treatment with the preparation.
    Drivers of vehicles and persons working with potentially dangerous mechanisms should be warned about the possibility of developing drowsiness while taking the preparation.

    Interactions

    Alcohol can potentiate the sedative effect of neuroleptics, therefore, during treatment with sulpiride, patients should refrain from drinking alcohol and using preparations containing ethyl alcohol.
    Levodopa has an antagonistic effect on neuroleptic preparations and vice versa. Patients with extrapyramidal symptoms due to the use of neuroleptic preparations should not be given levodopa. If an antipsychotic preparation is required in a patient taking levodopa for Parkinson's disease, it is recommended to choose a preparation with mild extrapyramidal effects, in particular chlorpromazine or levomepromazine.
    Antihypertensive preparations  may have an additive hypotensive effect and increase the risk of postural hypotension.
    CNS depressants (morphine derivatives, most H1 receptor blockers, barbiturates, benzodiazepines, non-benzodiazepine tranquilizers, clonidine and related compounds) potentiate the depriming effect of sulpiride.

    Overdose

    Dyskinetic manifestations with spasmodic torticollis, tongue protrusion and lockjaw. some patients sometimes develop severe manifestations of parkinsonism and coma. eglonil is partially excreted by hemodialysis. symptomatic treatment: resuscitation, intensive therapy with constant monitoring of respiration and cardiac activity (with an increase in the q-t interval), which must be carried out until the patient is completely recovered. with the development of severe extrapyramidal symptoms, anticholinergic preparations should be used.

    Storage conditions

    At a temperature of 15–30 °C.

    There are no reviews for this product.
    VEV Healthcare Store © 2017